Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

[1]  L. Esserman,et al.  Aggregate Cost of Mammography Screening in the United States: Comparison of Current Practice and Advocated Guidelines , 2014, Annals of Internal Medicine.

[2]  B. Kramer,et al.  Overdiagnosis in low-dose computed tomography screening for lung cancer. , 2014, JAMA internal medicine.

[3]  Donald R. Miller,et al.  Melanoma epidemic: an analysis of six decades of data from the Connecticut Tumor Registry. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Chang,et al.  Computer-Aided Diagnosis of Skin Lesions Using Conventional Digital Photography: A Reliability and Feasibility Study , 2013, PloS one.

[5]  Rongwei Fu,et al.  Screening for Lung Cancer With Low-Dose Computed Tomography: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation , 2013, Annals of Internal Medicine.

[6]  P. Choyke,et al.  Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer , 2013, Cancer.

[7]  Brian Reid,et al.  Overdiagnosis and overtreatment in cancer: an opportunity for improvement. , 2013, JAMA.

[8]  Ian M Thompson,et al.  Long-term survival of participants in the prostate cancer prevention trial. , 2013, The New England journal of medicine.

[9]  Barbara L. Smith,et al.  Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Chris I. Flowers,et al.  Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention , 2013, Breast Cancer Research and Treatment.

[11]  M. Chren,et al.  Treatment of nonfatal conditions at the end of life: nonmelanoma skin cancer. , 2013, JAMA internal medicine.

[12]  George W. Sledge,et al.  A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.

[13]  Brett M Coldiron,et al.  Analysis of Skin Cancer Treatment and Costs in the United States Medicare Population, 1996–2008 , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[14]  A. Bleyer,et al.  Effect of three decades of screening mammography on breast-cancer incidence. , 2012, The New England journal of medicine.

[15]  Lisa M. Schwartz,et al.  Cancer screening campaigns--getting past uninformative persuasion. , 2012, The New England journal of medicine.

[16]  Nola Hylton,et al.  Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Pépin,et al.  Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? , 2012, European urology.

[18]  L. Esserman,et al.  Breast cancer screening: the questions answered , 2012, Nature Reviews Clinical Oncology.

[19]  I. Thompson,et al.  Prostate cancer--uncertainty and a way forward. , 2012, The New England journal of medicine.

[20]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.

[21]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[22]  J. Bergh,et al.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Shibata.  Heterogeneity and Tumor History , 2012, Science.

[24]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[25]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[26]  Biao He,et al.  A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies , 2012, The Lancet.

[27]  B. Goff,et al.  Vignette-Based Study of Ovarian Cancer Screening: Do U.S. Physicians Report Adhering to Evidence-Based Recommendations? , 2012, Annals of Internal Medicine.

[28]  Marc E. Lenburg,et al.  Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2011, Breast Cancer Research and Treatment.

[29]  L. Esserman,et al.  P5-15-01: Words Matter: Influence of DCIS Diagnosis Terminology on Patient Treatment Decisions. , 2011 .

[30]  A. Fyles,et al.  S2-2: Luminal A Subtype Predicts Radiation Response in Patients with T1N0 Breast Cancer Enrolled in a Randomized Trial of Tamoxifen with or without Breast Radiation. , 2011 .

[31]  D. Miglioretti,et al.  Cumulative Probability of False-Positive Recall or Biopsy Recommendation After 10 Years of Screening Mammography , 2011, Annals of Internal Medicine.

[32]  Julliette M. Buckley,et al.  Lumpectomy Cavity Shaved Margins Do Not Impact Re-excision Rates in Breast Cancer Patients , 2011, Annals of Surgical Oncology.

[33]  A. Glas,et al.  Impact of mammographic screening on the detection of good and poor prognosis breast cancers , 2011, Breast Cancer Research and Treatment.

[34]  L. Esserman,et al.  Characterizing the impact of 25 years of DCIS treatment , 2011, Breast Cancer Research and Treatment.

[35]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[36]  Prateek Sharma,et al.  American Gastroenterological Association medical position statement on the management of Barrett's esophagus. , 2011, Gastroenterology.

[37]  Prateek Sharma,et al.  American Gastroenterological Association technical review on the management of Barrett's esophagus. , 2011, Gastroenterology.

[38]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[39]  Karla Kerlikowske,et al.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.

[40]  H. Welch,et al.  Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.

[41]  W. Sakr,et al.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. , 2010, The Journal of urology.

[42]  E. Chang,et al.  Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Brett M. Coldiron,et al.  Incidence estimate of nonmelanoma skin cancer in the United States, 2006. , 2010, Archives of dermatology.

[45]  B. Reid,et al.  Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis , 2010, Nature Reviews Cancer.

[46]  L. Esserman,et al.  Rethinking screening for breast cancer and prostate cancer. , 2009, JAMA.

[47]  D. Greenberg,et al.  Melanoma epidemic: a midsummer night’s dream? , 2009, The British journal of dermatology.

[48]  T. Tuttle,et al.  Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Dillner,et al.  Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. , 2009, Journal of the National Cancer Institute.

[50]  Robert Axelrod,et al.  Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. , 2008, Translational oncology.

[51]  P. Bach.  Is our natural-history model of lung cancer wrong? , 2008, The Lancet. Oncology.

[52]  J. Cronan.  Thyroid nodules: is it time to turn off the US machines? , 2008, Radiology.

[53]  John T. Wei,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[54]  Ugo Pastorino,et al.  Computed tomography screening and lung cancer outcomes. , 2007, JAMA.

[55]  Kamran Ayub,et al.  NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma , 2007, PLoS medicine.

[56]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[57]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  G. Haas,et al.  The role of prevalence in the diagnosis of prostate cancer. , 2006, Cancer control : journal of the Moffitt Cancer Center.

[59]  E. Bergstralh,et al.  Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. , 2006, Journal of the National Cancer Institute.

[60]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[61]  E. Mazzaferri.  Managing small thyroid cancers. , 2006, JAMA.

[62]  Ziding Feng,et al.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.

[63]  Vishal Ghevariya,et al.  The Rate of Adenocarcinoma in Endoscopically Removed Colorectal Polyps , 2005, The American surgeon.

[64]  Lisa M. Schwartz,et al.  Skin biopsy rates and incidence of melanoma: population based ecological study , 2005, BMJ : British Medical Journal.

[65]  G. Byrnes,et al.  Incidental lung cancers identified at coronial autopsy: implications for overdiagnosis of lung cancer by screening. , 2005, Respiratory medicine.

[66]  Floyd J Fowler,et al.  Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. , 2002, The American journal of medicine.

[67]  M. Tuchman,et al.  Screening of infants and mortality due to neuroblastoma. , 2002, The New England journal of medicine.

[68]  Helen C. Cowley,et al.  Improving the accuracy of mammography: volume and outcome relationships. , 2002, Journal of the National Cancer Institute.

[69]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[70]  Kenneth K Wang,et al.  Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.

[71]  R. Sampliner,et al.  Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.

[72]  E T Stewart,et al.  Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. , 1993, The New England journal of medicine.

[73]  G. Rhoads.  The Epidemiologic Necropsy , 1987 .

[74]  C. Wells,et al.  The 'epidemiologic necropsy'. Unexpected detections, demographic selections, and changing rates of lung cancer. , 1987, JAMA.

[75]  K. Franssila,et al.  Occult papillary carcinoma of the thyroid. A “normal” finding in finland. A systematic autopsy study , 1985, Cancer.

[76]  W. Fletcher,et al.  Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. , 1985, American journal of surgery.

[77]  L. Woolner,et al.  Occult papillary carcinoma of the thyroid. , 1980, Archives of surgery.

[78]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[79]  Liying Zhang,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  A. McCullough,et al.  Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative. , 2006, Gastrointestinal endoscopy.

[81]  M P Osborne,et al.  Breast carcinoma in situ. , 1989, Archives of surgery.